• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Lantern Pharma Inc. - Common Stock (NQ:LTRN)

    4.680 +0.240 (+5.41%)
    Streaming Delayed Price Updated: 1:58 PM EDT, Aug 1, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 184,041
    Open 4.330
    Bid (Size) 4.670 (3)
    Ask (Size) 4.770 (1)
    Prev. Close 4.440
    Today's Range 4.054 - 4.900
    52wk Range 2.550 - 6.118
    Shares Outstanding 10,784,725
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Completes Targeted Enrollment for Phase 2 HARMONIC Trial in Japan
    Via Investor Brand Network
    Topics Artificial Intelligence
    Lantern Pharma Completes Targeted Enrollment for Lung Cancer Phase 2 Harmonic™ Clinical Trial in Japan for LP-300
    From Lantern Pharma Inc.
    Via Business Wire

    Performance

    YTD
    +41.8%
    +41.8%
    1 Month
    +48.6%
    +48.6%
    3 Month
    +29.3%
    +29.3%
    6 Month
    -2.7%
    -2.7%
    1 Year
    +11.4%
    +11.4%

    More News

    Read More
    AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Appoints Dr. Lee T. Schalop to Board to Bolster AI-Driven Precision Oncology
    Via Investor Brand Network
    Topics Artificial Intelligence
    Lantern Pharma Announces Appointment of Dr. Lee Schalop to Board of Directors
    From Lantern Pharma Inc.
    Via Business Wire
    Lantern Pharma Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
    Via ACCESS Newswire
    BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) Reports First Complete Response in Phase 1 LP-284 Trial for Aggressive DLBCL
    Via Investor Brand Network
    Topics Artificial Intelligence
    Lantern Pharma Reports Complete Response in Heavily Pre-Treated Lymphoma Patient with LP-284 in Phase 1 Clinical Trial
    From Lantern Pharma Inc.
    Via Business Wire
    BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Secures EU Patent for AI-Designed Cancer Drug LP-284
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    Lantern Pharma Secures EU Patent Allowance for LP-284, Bolstering Global IP Position for AI-Developed Cancer Therapy
    From Lantern Pharma Inc.
    Via Business Wire
    InvestorNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Taps IBN to Lead Corporate Communications Amid AI-Driven Oncology Pipeline Progress
    Via Investor Brand Network
    Topics Artificial Intelligence
    BioMedNewsBreaks – Lantern Pharma (NASDAQ: LTRN) Launches AI Module to Accelerate Development of Targeted Cancer Combination Therapies
    Via Investor Brand Network
    Topics Artificial Intelligence
    AINewsBreaks – Lantern Pharma (NASDAQ: LTRN) Launches AI Module to Accelerate Development of Targeted Cancer Combination Therapies
    Via Investor Brand Network
    Topics Artificial Intelligence
    Lantern Pharma Unveils Groundbreaking AI-Powered Module to Predict Activity and Efficacy of Combination Regimens in Clinical Cancer Treatment
    From Lantern Pharma Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    AINewsBreaks – Why Lantern Pharma Inc. (NASDAQ: LTRN) Is ‘One to Watch’
    Via Investor Brand Network
    Topics Artificial Intelligence
    Lantern Pharma Inc.’s (NASDAQ: LTRN) AI-Powered Platform Delivers Promising and Durable Results in Lung Cancer Trial
    Via Investor Brand Network
    Topics Artificial Intelligence
    InvestorNewsBreaks – Lantern Pharma Inc. (NASDAQ: LTRN) Reports Complete Response in Advanced NSCLC Patient in HARMONIC(TM) Trial
    Via Investor Brand Network
    Topics Artificial Intelligence
    Lung Cancer Patient in Lantern Pharma’s Harmonic Trial Shows Durable Complete Response in Target Cancer Lesions with Survival Continuing for Nearly Two Years
    From Lantern Pharma Inc.
    Via Business Wire
    Lantern Pharma Inc. (NASDAQ: LTRN) Is ‘One to Watch’
    Via Investor Brand Network
    Topics Artificial Intelligence
    BioMedNewsBreaks — Panna Sharma, Lantern Pharma CEO, Says FDA’s Elsa AI Rollout Underscores Urgency to Modernize
    Via Investor Brand Network
    Topics Artificial Intelligence
    BioMedNewsBreaks — Lantern Pharma Inc. (NASDAQ: LTRN) Highlights LP-184 Preclinical Success in Pediatric Brain Cancer ATRT
    Via Investor Brand Network
    Topics Artificial Intelligence
    Lantern Pharma's LP-184 Shows Promising In Vivo Activity in Atypical Teratoid Rhabdoid Tumors (ATRT) at SNO Pediatric Conference, Further Validating Rare Pediatric Disease Designation and Pathway to Clinical Trials
    From Lantern Pharma Inc.
    Via Business Wire
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Lantern Pharma Reports First Quarter 2025 Financial Results and Business Updates
    From Lantern Pharma Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Lantern Pharma Inc. - Common Stock publicly traded?
    Yes, Lantern Pharma Inc. - Common Stock is publicly traded.
    What exchange does Lantern Pharma Inc. - Common Stock trade on?
    Lantern Pharma Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Lantern Pharma Inc. - Common Stock?
    The ticker symbol for Lantern Pharma Inc. - Common Stock is LTRN on the Nasdaq Stock Market
    What is the current price of Lantern Pharma Inc. - Common Stock?
    The current price of Lantern Pharma Inc. - Common Stock is 4.680
    When was Lantern Pharma Inc. - Common Stock last traded?
    The last trade of Lantern Pharma Inc. - Common Stock was at 08/01/25 01:58 PM ET
    What is the market capitalization of Lantern Pharma Inc. - Common Stock?
    The market capitalization of Lantern Pharma Inc. - Common Stock is 50.47M
    How many shares of Lantern Pharma Inc. - Common Stock are outstanding?
    Lantern Pharma Inc. - Common Stock has 50M shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.